Immunocore reports third quarter financial results and provides a business updateKIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q ...
With the planet’s forests facing numerous threats, advanced monitoring techniques are essential to preserve these crucial ...
Joey Wagner of BluePrint Supply Chain explains why it's critical to have a reliable quality assurance program and consistent ...
But after gaining more than 20 pounds during undergraduate and graduate school and feeling unhappy with her weight, the ...
Prescriptions of this GLP-1 class of diabetes and weight-loss medications ... monitor trade-offs between pharmacologic and ...
Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...
News Medical on MSN9d
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMRChronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the ...
Officials reported the Berlin brushfire on Lamentation Mountain is contained Monday though they continue to suppress further ...
Weight management medications are transforming the landscape of obesity treatment, with semaglutide emerging as a ...
Conservation scientists monitoring the wildlife on Orkney have reported increased evidence of Orkney Voles and increased ...
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback